Saudi Arabia Artificial heart Market Overview, 2031

Saudi Arabia’s market for artificial hearts and mechanical circulatory-support devices has grown quickly as major tertiary hospitals expand their cardiac-surgery capabilities and adopt newer ventricular assist devices (VADs) and, in select cases, total artificial hearts for patients who need bridge-to-transplant or long-term support. This momentum is fueled by a rising burden of heart failure and ischemic heart disease across the Gulf, along with better diagnostics, faster referrals, and a growing number of patients who qualify for advanced therapy. These technologies sit within a wider ecosystem of cardiac devices including pacemakers, implantable defibrillators, and coronary-care systems allowing hospitals to leverage shared expertise across perfusion teams, cardiac programs, and rehabilitation services. Market access and regulatory pathways are guided by the Saudi Food and Drug Authority’s framework for high-risk medical devices, including updated rules for digital and AI-enabled systems, which shape how implants are classified, authorized, and represented locally. When choosing devices, clinicians and hospitals weigh factors such as biocompatibility, pump durability, infection-control requirements, and the level of specialized training needed, while certifications and centre-of-excellence status often determine which technologies are preferred. Cultural attitudes toward organ donation and transplantation also influence treatment pathways, affecting how often VADs are used as temporary support versus long-term therapy. High-profile cases including complex procedures and pediatric interventions have showcased the growing expertise within Saudi cardiac centers, strengthening their role as regional referral hubs and accelerating technology adoption across the wider Middle East and Africa.

According to the research report, "Saudi Arabia Artificial heart Overview, 2031," published by Bonafide Research, the Saudi Arabia Artificial heart is anticipated to grow at more than 15.5% CAGR from 2026 to 2031.Several well-established Saudi distributors and medical-supply companies especially those working closely with major cardiac centers play a key role in making ventricular assist devices, total artificial hearts, and related consumables accessible in the country. These partners stand out by providing strong after-sales service, hands-on clinical training, and support with the SFDA’s regulatory and registration processes, which are essential for high-risk cardiac implants. Their product portfolios usually span implantable LVADs and RVADs, temporary circulatory-support systems such as ECMO and Impella-type devices, along with drivelines, connectors, disposables, and technical services like device maintenance and remote monitoring. Hospitals typically procure these devices through importer distributor networks tied to government tenders, though long-term service contracts, bundled pricing options, and even short-term leasing arrangements are sometimes used for critical care needs. The landscape is shifting as hospitals increasingly move toward durable continuous-flow pumps and expand the use of temporary mechanical support in acute cardiac cases, opening doors for local assembly partnerships, technology-transfer projects, and advanced training programs with global manufacturers. Instead of consumer-style marketing, promotions rely on cardiology conferences, clinical demonstrations, and collaboration with leading physicians who influence hospital decision-making. Distribution remains highly specialized, centered on advanced cardiac hospitals, with international manufacturers supplying the core devices and local partners managing logistics, installation, servicing, and spare-parts availability. The high cost of device programs, rigorous SFDA requirements, and the need for experienced cardiac-surgery teams, while constraints around organ donation and transplant availability shape how frequently devices are used for long-term support versus bridge-to-transplant care.

In Saudi Arabia, temporary Total Artificial Hearts (TAHs) have been used in tertiary cardiac centers, such as the 2023 SynCardia implantation, primarily serving patients with end-stage biventricular failure as a bridge to transplant, while fully implantable designs remain under development and clinical trials. Hospitals source TAHs through specialized distributors and surgical programs, with device selection influenced by factors such as surgical compatibility, haemocompatibility, infection risk at drivelines or ports, external controller logistics, and the availability of transplant pathways, which together determine whether therapy is temporary or longer-term. Left and right Ventricular Assist Devices (VADs), including durable LVADs, continue to be widely adopted for advanced-heart-failure patients, functioning either as destination therapy or as a bridge to transplant based on patient candidacy. Modern continuous-flow LVADs, including HeartMate 3 implants with robotic-assisted procedures, have been reported in regional practice, alongside market offerings that include implantable pumps with external controllers, consumable driveline components, telemetry and monitoring services, and hospital-based training and aftercare. Adoption and procurement depend heavily on center credentialing, surgeon experience, service contracts, and long-term device performance, including thrombosis, hemolysis, and durability. Research into bioartificial heart systems, such as decellularized scaffolds reseeded with patient cells, 3D-bioprinted cardiac patches, and stem-cell-based myocardium regeneration, remains largely preclinical, with regulatory pathways requiring combination-product considerations and clinical adoption contingent on scalable manufacturing and functional safety data. Emerging devices of note include Aeson (CARMAT) bionic-heart prostheses in compassionate-use cases, BiVACOR’s magnetically levitated rotor TAH under early regulatory milestones, and ongoing trials for HeartMate 3 in complex scenarios. A growing number of smaller innovators are also exploring pulsatile, fully implantable, flow-synchronizing, and biohybrid devices aimed at reducing infection risk from external drivelines and improving haemocompatibility, with most projects still in feasibility or early clinical stages.

Patients with advanced heart failure or acute cardiac crises often rely on mechanical circulatory-support devices tailored to specific clinical needs. In cases where a donor heart is not immediately available, Left Ventricular Assist Devices (LVADs) or other ventricular assist devices (VADs) can sustain blood flow until transplantation, and in rare situations, Total Artificial Hearts (TAHs) are used when both ventricles are failing. For patient’s ineligible for transplant due to age, comorbidities, or donor shortages, VADs may provide permanent circulatory support, offering long-term therapy that has become increasingly viable with advances in device durability, biocompatibility, and follow up care. Short-term support is provided for patients whose heart function may recover, such as those with acute myocarditis, post-operative cardiac dysfunction, or temporary shock, allowing the heart to rest with the potential for device explantation once recovery occurs. In emergent scenarios like cardiogenic shock, post-cardiotomy failure, or severe decompensated heart failure, temporary mechanical circulatory assistance with percutaneous pumps, ECMO systems, or external VADs stabilizes the patient and maintains organ perfusion while decisions are made or recovery progresses. LVADs and VADs offer flexibility across all these applications, whereas TAHs are mostly limited to bridge to transplant or temporary support in biventricular failure. Temporary devices primarily support acute, short-duration needs or serve as bridges to recovery or decision-making, providing critical stabilization before more durable interventions. Each application influences clinical management, from careful monitoring and center expertise during bridge-to-transplant therapy, to long-term management and quality-of-life considerations in destination therapy, to conditional short-term support in bridge-to-recovery cases, and rapid stabilization during emergent mechanical assistance.

Equipped with fully staffed operating theatres, perfusion teams, anesthesiologists, and intensive care units, cardiac surgery centers handle the implantation of devices such as Left Ventricular Assist Devices (LVADs), Total Artificial Hearts (TAH), and other mechanical circulatory-support systems, which require highly specialized surgical and post-operative capabilities. Following surgery, these centers manage acute care, including early patient monitoring and stabilization, ensuring that mechanical support is safely initiated. Patients with long-term device needs, such as LVADs used for destination therapy, often receive ongoing management at specialized heart-failure treatment facilities, where regular follow-ups, device maintenance, complication monitoring including thrombosis and driveline infections and rehabilitation are conducted. Emerging shared-care models allow these specialized centers to coordinate with implantation hospitals, extending continuity of care to patients living far from the primary surgical facility. Transplant centers play a critical role in evaluating candidates, coordinating wait-lists, and performing surgeries, frequently using mechanical support devices as a bridge-to-transplant to stabilize patients while awaiting donor hearts. In cases where centers manage both transplant and mechanical support programs, integration ensures precise timing of implantation or explantation and structured post-transplant follow-up. The majority of procedures remain hospital-based due to the complexity of surgeries and intensive post-operative care, with device selection and care pathways closely tied to the presence of multidisciplinary teams, long-term monitoring infrastructure, and comprehensive post-implant programs, which concentrate adoption within well-equipped, centralized cardiac facilities.



Considered in this report
• Historic year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Saudi Arabia Artificial heart Market with its value and forecast along with its segments
• Country-wise Artificial heart Market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Total Artificial Heart (TAH)
• Ventricular Assist Devices (VADs)
• Bioartificial Heart Systems

By Application
• Bridge-to-Transplant Therapy
• Destination Therapy
• Bridge-to-Recovery Support
• Temporary Mechanical Circulatory Assistance

By End User
• Cardiac Surgery Centers
• Specialized Heart Failure Treatment Facilities
• Transplant Centers